S&P Futures
3,614.25-22.25(-0.61%)Dow Futures
29,657.00-217.00(-0.73%)Nasdaq Futures
12,227.75-29.75(-0.24%)
Atara Biotherapeutics, Inc. (ATRA)
Chart Events
Performance Outlook
| Previous Close | 22.99 |
| Open | 23.05 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's Range | 22.97 - 23.69 |
| 52 Week Range | 4.52 - 24.00 |
| Volume | 367,093 |
| Avg. Volume | 851,034 |
| Market Cap | 1.808B |
| Beta (5Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.53 |
| Earnings Date | Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
Fair Value
Related Research
- Business Wire
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences.
- Business Wire
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will present for the first time 15-month safety and efficacy data from all patients in the two highest dose cohorts of the Phase 1a open-label extension (OLE) study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The results are featured in a poster presentation at the European Charcot Foundation (ECF) 28th Annual Meeting, held November 15-19, 2020.
- Investor's Business Daily
Atara Biotherapeutics Moves With Rising Relative Price Strength
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Atara Biotherapeutics, which saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 84 to 92. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
